Table 3 Neurometabolite concentrations, with creatine as reference.

From: Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients

 

HC

FEP

t

p

Neurometabolitesa

Baseline

NAA/Cr

1.55 (0.28)

1.48 (0.25)

0.72

0.48

Glx/Cr

0.84 (0.16)

0.81 (0.11)

0.70

0.49

Cho/Cr

0.73 (0.17)

0.74 (0.10)

−0.14

0.89

Week 6

NAA/Cr

1.57 (0.22)

1.49 (0.26)

0.87

0.39

Glx/Cr

0.87 (0.10)

0.83 (0.13)

0.96

0.35

Cho/Cr

0.72 (0.15)

0.73 (0.09)

−0.04

0.97

Week 16

NAA/Cr

1.48 (0.11)

1.41 (0.13)

1.48

0.15

Glx/Cr

0.80 (0.10)

0.81 (0.09)

−0.30

0.77

Cho/Cr

0.70 (0.08)

0.71 (0.08)

−0.43

0.67

  1. HC healthy control, FEP first-episode psychosis patient, NAA N-acetyl-aspartate, Glx glutamate + glutamine, Cho choline, Cr creatine.
Back to article page